第 44 卷第 2 期 |  | Vol. 44 No. 2 | 2014 年 4 月 | Apr 2014 |
|
所屬欄目:醫藥及中間體
囊性纖維化治療新藥Ivacaftor的合成 |
商青姿
(天津大學(xué) 藥物科學(xué)與技術(shù)學(xué)院, 天津 300072) |
摘 要:Ivacaftor是被FDA批準用于由G551D基因突變引起的囊性纖維化的治療藥物。以2,4-二叔丁基苯酚為原料,經(jīng)酯化保護、硝化、水解脫保護、硝基還原得到關(guān)鍵中間體2,4-二叔丁基-5-氨基苯酚;苯胺和乙氧亞甲基丙二酸二乙酯經(jīng)Gould-Jacobs反應得到4-氧代-1,4-二氫喹啉-3-羧酸。2,4-二叔丁基-5-氨基苯酚與4-氧代-1,4-二氫喹啉-3-羧酸縮合得到Ivacaftor,總收率約13%(以苯胺計)。 |
關(guān)鍵詞:Ivacaftor;囊性纖維化;合成 |
中圖分類(lèi)號:TQ225.24 文獻標識碼:A 文章編號:1009-9212(2014)02-0028-06 |
|
Synthesis of Ivacaftor-A Cystic Fibrosis Drug |
SHANG Qing-zi
(School of Pharmaceutical Science and Technology, Tianjin University, Tianjin 300072, China) |
Abstract:Ivacaftor(1) has been approved by FDA for the treatment of cystic fibrosis caused by G551D gene mutation. It was synthesized by the reaction of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid(5)with 5-amino-2,4-di-tert-butylphenol(12) in overall yield of 13% (based on aniline). 5 was prepared via Gould-Jacobs reaction from aniline and diethyl-2-(ethoxymethylene) malonate. 12 was obtained from 2,4-di-tert-butylphenol via ester formation, nitration, ester hydrolysis and the reduction of the nitro group. |
Key words:Ivacaftor; cystic fibrosis; synthesis |
|
基金項目:天津市科委資助項目(11ZCGHHZ00800)。
|
作者簡(jiǎn)介:商青姿(1987-),女,山東德州人,碩士研究生,研究方向:藥物化學(xué)(Email:skzqingzi@126.com)。
|
收稿日期: 2014-04-1
|
|